The use of sirolimus to treat Kaposi's sarcoma in an HIV‐negative rheumatoid arthritis patient on disease‐modifying drug therapies

By  

INTERNATIONAL JOURNAL OF DERMATOLOGY, Vol. 54, Iss. 10, 2015-10 ,pp. : 1188-1190

John Wiley & Sons Inc

Access to resources Recommend Favorite

Disease‐Modifying Antirheumatic Drug Use and the Risk of Incident Hyperlipidemia in Patients With Early Rheumatoid Arthritis: A Retrospective Cohort Study

By  

ARTHRITIS CARE AND RESEARCH, Vol. 67, Iss. 4, 2015-04 ,pp. : 457-466

John Wiley & Sons Inc

Access to resources Recommend Favorite

Acquired Haemophilia A and Kaposi’s Sarcoma in an HIV-Negative, HHV-8-Positive Patient: A Discussion of Mechanism and Aetiology

By  

Acta Haematologica, Vol. 124, Iss. 1, 2010-07 ,pp. : 40-43

Karger

Access to resources Recommend Favorite

UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug

By Kielhorn Adrian   Porter Duncan   Diamantopoulos Alexander   Lewis Gavin  

Current Medical Research and Opinion, Vol. 24, Iss. 9, 2008-09 ,pp. : 2639-2650

Informa Healthcare

Access to resources Recommend Favorite

Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study

By Gibofsky Allan   Palmer William R.   Goldman John A.   Lautzenheiser Richard L.   Markenson Joseph A.   Weaver Arthur   Schiff Michael H.   Keystone Edward C.   Paulus Harold E.   Harrison Melanie J.   Whitmore James B.   Leff Jonathan A.  

Current Medical Research and Opinion, Vol. 22, Iss. 1, 2006-01 ,pp. : 169-183

Informa Healthcare

Access to resources Recommend Favorite